Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving / Saul Shiffman (2000)  

Public Titre : Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving Type de document : document électronique Auteurs : Saul Shiffman, Auteur ; C.A. Elash, Auteur ; Stephanie M. Paton, Auteur ; Chad J. Gwaltney, Auteur ; Jean A. Paty, Auteur ; D.B. Clarke, Auteur ; K.S. Liu, Auteur ; Michael E. Di Marino, Auteur Editeur : Society for the study of addiction to alcohol and other drugs Année de publication : 2000 Collection : Addiction num. 95(8) Importance : p.1185-1195 Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:efficacité du sevrage [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:patch à la nicotine Index. décimale : TA 6.2.3.1.2 Transcutané Résumé : Aims: To compare a transdermal nicotine patch designed for 24-hour wear with one designed for 16-hour wear for relief of craving and withdrawal, particularly in the morning hours. Design: Smokers were randomly assigned to use one of two common patch regimens: NicoDerm/NiQuitin (24-hour wear, 21 mg nicotine) or Nicotrol/Nicorette (16-hour wear, 15 mg). In a double-dummy design, participants wore two patches during the day, one active, one placebo and one patch while sleeping. Setting: A smoking cessation research clinic. Participants: Two hundred and forty-four smokers who suffered morning cravings. Intervention: Two patch formulations approved and marketed for over-the-counter use in the US--NicoDerm CQ (labeled as 21 mg over 24 hours) and Nicotrol (labeled as 15 mg over 16 hours)--were each used according to its instructions. Smokers also received behavioral counseling. Measurements: For a week of baseline and 2 weeks after quitting, smokers used palm-top computers to assess craving and withdrawal symptoms several times each day. Findings: The 21 mg/24-hour patch yielded consistently better control of craving, not only during the morning hours, but throughout the day, and over the 2-week period of abstinence. Additionally, the 21 mg/24-hour patch yielded greater reductions in anxiety, irritability and restlessness. Smokers using the 21 mg/24-hour dosing regimen also experienced longer abstinence than those using the 15 mg/16-hour patch. Conclusions: These findings demonstrate that 24-hour dosing with a 21 mg patch affords superior relief of craving and withdrawal during the first 2 weeks of abstinence, when symptoms are at their peak, and when relapse is most likely. They confirm the importance of dosing parameters in nicotine replacement products. En ligne : https://doi.org/10.1046/j.1360-0443.2000.95811855.x Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10343

Aucun avis, veuillez vous identifier pour ajouter le vôtre !

Real-world efficacy of prescription and over-the-counter nicotine replacement therapy / Saul Shiffman (2001)  

Public Titre : Real-world efficacy of prescription and over-the-counter nicotine replacement therapy Type de document : document électronique Auteurs : Saul Shiffman, Auteur ; Clyde N. Rolf, Auteur ; Stephen J. Hellebusch, Auteur ; Jane Gorsline, Auteur ; W. Gorodetzky, Auteur ; Yu-Kun Chiang, Auteur ; Debra S. Schleusener, Auteur ; Michael E. Di Marino, Auteur Editeur : Society for the study of addiction to alcohol and other drugs Année de publication : 2001 Collection : Addiction num. 97 Importance : p.505-516 Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:chewing-gum [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:patch à la nicotine [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique Index. décimale : TA 6.2.3.1 Substitution nicotinique Résumé : Aims To assess smoking cessation rates achieved with nicotine gum and patch in simulated over-the-counter (OTC) and actual prescription (Rx) settings. Design Separate open-label studies with gum and patch in OTC and Rx settings. Participants There were multiple samples: OTC gum: 2981 smokers; OTC patch: 2367; Rx gum: 324; Rx patch: 669. Interventions All smokers received active nicotine replacement. In the OTC setting, smokers self-selected doses of nicotine gum (2 or 4mg Nicorette®) or patch (21, 14 or 7mg NicoDerm® CQ). No intervention was provided. In the Rx setting, smokers were prescribed gum or patch by their physician. Measurements Biochemically verified continuous smoking abstinence was assessed at 6 weeks (28-day abstinence) and 6 months. Findings OTC success rates were consistently higher than Rx rates: differences were significant at 6 weeks for both patch [OR = 1.45 (1.05–1.98)] and gum [OR = 2.92 (1.58–5.40)], and remained significant at 6 months for patch [OR = 3.63; (1.74–7.61)] but not gum [OR = 1.37; (0.73–2.58)]. Among OTC gum users, 16.1% were abstinent at 6 weeks and 8.4% at 6 months. For Rx gum users, abstinence rates were 7.7% at 6 weeks and 7.7% at 6 months. With OTC patch, 19.0% were abstinent at 6 weeks and 9.2% at 6 months. With Rx patch, abstinence rates were 16.0% at 6 weeks and 3.0% at 6 months. Conclusions Smoking cessation rates achieved with nicotine gum and patch under OTC conditions were as good as those under real-world prescribing conditions. En ligne : https://doi.org/10.1046/j.1360-0443.2002.00141.x Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10342

Aucun avis, veuillez vous identifier pour ajouter le vôtre !